Trial Design Considerations to Increase Older Adult Accrual to National Cancer Institute Clinical Trials.


Journal

Journal of the National Cancer Institute. Monographs
ISSN: 1745-6614
Titre abrégé: J Natl Cancer Inst Monogr
Pays: United States
ID NLM: 9011255

Informations de publication

Date de publication:
15 12 2022
Historique:
received: 06 07 2022
revised: 19 08 2022
accepted: 26 09 2022
entrez: 15 12 2022
pubmed: 16 12 2022
medline: 17 12 2022
Statut: ppublish

Résumé

Although adults aged 65 years or older make up a strong majority of cancer patients, their underrepresentation in cancer clinical trials leads to the lack of representative data to guide evidence-based therapeutic decisions in this patient population. The Trial Design Working Group, convened as part of the workshop titled, Engaging Older Adults in the National Cancer Institute Clinical Trials Network: Challenges and Opportunities, recommended study designs and design elements that could improve accrual of older adults in National Cancer Institute-funded clinical trials. These include trials that are specifically designed to enroll older adults, trials that include a cohort of older patients (parallel cohort, stratified cohort, or embedded cohort), and trials with pragmatic design elements to facilitate enrollment of older adults. This manuscript provides brief descriptions of the recommended designs, examples of successful trials, and considerations for implementation of these designs. As with any clinical trial, the scientific questions and trial objectives should drive the study design, the selection of endpoints and intervention, and eligibility criteria. When designing trials that include older adults, the heterogeneity of fitness levels is an important consideration as fitness can influence accrual rates and outcomes. Appropriately incorporating geriatric assessments can help identify the optimal subset of older patients for inclusion and minimize selection bias. Incorporating pragmatic design elements to reduce the burden on trial participants as well as on accruing sites and retaining essential elements to ensure that the main goal of the trial can be accomplished can enhance enrollment without compromising the integrity of trials.

Identifiants

pubmed: 36519818
pii: 6908749
doi: 10.1093/jncimonographs/lgac023
pmc: PMC9949574
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

135-141

Subventions

Organisme : NIA NIH HHS
ID : K76 AG074918
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015083
Pays : United States

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Références

Oncologist. 2019 Jun;24(6):e284-e291
pubmed: 30975921
JAMA Oncol. 2021 Jun 1;7(6):869-877
pubmed: 33983395
N Engl J Med. 2019 Aug 1;381(5):432-443
pubmed: 31365801
Clin Cancer Res. 2021 May 1;27(9):2424-2429
pubmed: 33563633
N Engl J Med. 2009 May 14;360(20):2055-65
pubmed: 19439741
J Geriatr Oncol. 2020 Jan;11(1):107-113
pubmed: 31668825
JAMA. 2004 Jun 9;291(22):2720-6
pubmed: 15187053
J Clin Oncol. 2015 Nov 10;33(32):3826-33
pubmed: 26195697
BMJ. 2015 May 08;350:h2147
pubmed: 25956159
N Engl J Med. 2018 Dec 27;379(26):2517-2528
pubmed: 30501481
N Engl J Med. 1999 Dec 30;341(27):2061-7
pubmed: 10615079
J Natl Cancer Inst Monogr. 2022 Dec 15;2022(60):142-150
pubmed: 36519816
Haematologica. 2014 Jan;99(1):4-5
pubmed: 24425687
Lancet. 2021 Nov 20;398(10314):1894-1904
pubmed: 34741815
J Clin Oncol. 2004 Nov 15;22(22):4626-31
pubmed: 15542812
J Clin Oncol. 2006 Jan 1;24(1):141-4
pubmed: 16330670
Blood Adv. 2022 Jun 28;6(12):3812-3820
pubmed: 35420672

Auteurs

Jennifer Le-Rademacher (J)

Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, USA.

Supriya Mohile (S)

Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.

Joseph Unger (J)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Matthew F Hudson (MF)

Prisma Health, Greenville, SC, USA.

Jared Foster (J)

Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA.

Stuart Lichtman (S)

Previously MSKCC, New York, NY, USA.

Efrat Dotan (E)

Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

Martine Extermann (M)

Moffitt Cancer Center, Tampa, FL, USA.

Kevin Dodd (K)

Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA.

William Tew (W)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Heidi Klepin (H)

Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Tanya M Wildes (TM)

Cancer & Aging Research Group, St Louis, MO, USA.

Mina S Sedrak (MS)

Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, USA.

Aminah Jatoi (A)

Department of Oncology, Mayo Clinic, Rochester, MN, USA.

Richard F Little (RF)

Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH